Pulmonology

A COPD care bundle delivered by a multidisciplinary health care team can reduce hospital readmission rates for acute exacerbations of COPD (AECOPD).

Montelukast/levocetirizine combination therapy demonstrates safety and efficacy in phase 3 clinical trial for the treatment of patients with perennial allergic rhinitis who have mild-to-moderate asthma.

Before biologics are implemented, what should physicians be doing to ensure asthma control in their patients?

The addition of a couple of new drug classes at the turn of the century have given clinicians the greenlight to stack therapies at initial treatment.

There’s a challenge to achieve control in some asthma patients since the disease is heterogenous—both allergic and non-allergic triggers can initiate Type 2 inflammatory pathways that can drive pathology.

Joshua Denson, MD, MS, discusses the comorbidities associated with asthma.

Now that real-world data registries are being compiled, the constriction-limiting drug class is now going through personalizations including new titration strategies.

Antonion R. Anzueto, MD, covers the latest research regarding biomarkers in COPD, outlining possible avenues of investigation and addressing regional causes of the disease.

What makes the monoclonal antibody so enticing to the asthma community?

A 200 mg dose of the monoclonal antibody was also shown to significantly reduce ashtma exacerbations over 1 year versus placebo.

A retrospective review of rural region's hospitals found that even the discharge time of day could be associated with a greater chance of readmission.

Gram-negative bacteria excluding Pseudomonas Aeruginosa has been associated with greater rates of patient mortality, vasopressor administration, and ICU admission.

Investigators found that treating for CSA in the patient population significantly decreases mortality risk—despite previous clinical warnings.

Investigators have shared new disparities of characteristics in men and women with differing severities of respiratory arousal threshold.

Women are less likely to be administered lung protective tidal volumes (TVs) when being considered as a lung donor.

More IMPACT trial results shows Trelegy Ellipta has benefits for both reversible and nonreversible COPD patients in exacerbations and lung function versus dual therapy.

Data show that while women are underrepresented as fellows of the American College of Chest Physicians, the volume of women applying is increasing.

A new study found that Medicare Part D formulary shifts sometimes result in asthma patients forgoing controller therapy altogether.

The association between moderate hyperbilirubinemia and childhood asthma and lack of association with higher bilirubin levels indicates the association is not causal.

It’s long been established that obesity can lead to asthma, but new research suggests asthma can also lead to obesity.

Upon finding pH and oxygen may influence how antibiotics perform in CF lung infections, investigators suggest a one-size-fits-all therapy approach may not be the best treatment.

The pulmonologist and senior medical advisor, American Lung Association, highlights the necessary steps of smoking cessation practices as well as the unknown surrounding e-cigarettes.

The new formulation, known as Xolair PFS, will be available in the US by the end of the year.

The FDA has approved a 0.15mg dosage of Symjepi, an epinephrine injection, for the emergency treatment of serious allergic reactions in children.

How can caregivers improve their management of treatments—both in cost and in availability—for children in need of help due to asthma.